Research & Publications: Peer-Reviewed Stem Cell & Exosome Therapy Studies
Reviewed By Stem Cell Care India Medical Team · Sourced from PubMed / PubMed Central · Last updated 24 August 2026
A curated, condition-by-condition library of systematic reviews, meta-analyses and clinical studies on cell-based and exosome-based approaches — organised so patients, referring doctors, and researchers can read the underlying science in one place.
- What this page is: a library of 18 independent, peer-reviewed studies on stem cell and exosome therapy, covering Parkinson's disease, cerebral palsy, ALS, multiple sclerosis, spinal cord injury, traumatic brain injury, osteoarthritis, rheumatoid arthritis, diabetic foot ulcers, liver cirrhosis, chronic kidney disease, COPD, chronic heart failure, vision loss (retinitis pigmentosa, Stargardt disease, age-related macular degeneration & optic neuropathy), bone marrow transplant, MSC-based immunotherapy for autoimmune disease, exosome-based drug delivery, and exosome therapy for hair loss.
- Where the studies come from: every citation links directly to PubMed or PubMed Central (PMC), the U.S. National Library of Medicine's databases.
- What it is not: this is not Stem Cell Care India's own clinical trial data, and it is not medical advice.
- Regulatory status in India: under current ICMR guidelines, most stem cell applications remain investigational rather than approved cures.
This library is for informational purposes only and does not constitute medical advice. Insurance typically does not cover investigational therapies. Updated 24th August 2026.
What does the research say about stem cell therapy for neurological conditions?
Pooled trial data on Parkinson's disease, cerebral palsy, ALS, multiple sclerosis, spinal cord injury, traumatic brain injury, and ischaemic stroke — summarised from independent systematic reviews and meta-analyses indexed on PubMed Central.
Cell therapy for Parkinson's disease — systematic review & meta-analysis
Quick answer: A 2023 meta-analysis found early signs of benefit from cell-based therapy for Parkinson's disease, most notably in patients who still respond to levodopa.
This review pooled results across multiple clinical trials of cell-based therapy for Parkinson's disease, while flagging the need for larger, higher-quality trials before firmer conclusions can be drawn. See our Parkinson's Disease treatment page for how this evidence relates to our protocol.
Efficacy & safety of stem cell therapy in cerebral palsy — systematic review & meta-analysis
Quick answer: A 2022 meta-analysis found improved motor function scores at 3, 6 and 12 months in children with cerebral palsy, with no significant rise in adverse events.
Pooling outcomes from trials in children with cerebral palsy, this analysis found measurable gains in motor function, with adverse event rates comparable to control groups. See our Cerebral Palsy treatment page for related protocol information.
MSC safety & clinical efficacy across three neurological conditions
Quick answer: A 2022 review found mesenchymal stem cell treatment generally safe across spinal cord injury, multiple sclerosis, and ischaemic stroke, though efficacy varied by condition.
This review assessed mesenchymal stem cell (MSC) treatment for traumatic spinal cord injury, multiple sclerosis and ischaemic stroke together, describing a generally favourable safety profile overall. Related reading: Multiple Sclerosis, Stroke, and Spinal Cord Injury treatment pages.
MSC-based therapies across five well-studied neurological disorders — systematic review
Quick answer: A 2024 systematic review of 43 studies found mesenchymal stem cell transplantation generally safe and well-tolerated across ALS, Parkinson's, MS, spinal cord injury and traumatic brain injury.
Reviewing 43 manuscripts of clinical data, this analysis focused specifically on safety, tolerability and reported therapeutic benefit across five distinct neurological conditions. See our ALS/MND treatment page and Traumatic Brain Injury treatment page for related protocol information.
- Across all four neurological reviews, safety profiles were generally favourable compared to control groups.
- Parkinson's disease response appears strongest in patients who still respond to levodopa.
- Cerebral palsy studies showed motor-function gains sustained out to 12 months.
- The broadest review (43 studies) spans ALS, Parkinson's, MS, spinal cord injury and traumatic brain injury together, focused specifically on safety and tolerability.
- Efficacy varies meaningfully by condition — these conditions should not be treated as a single evidence pool.
What does the research say about stem cell therapy for osteoarthritis & rheumatoid arthritis?
Joint, cartilage and autoimmune-related evidence, drawn from pooled functional-outcome, pain, and disease-activity data across included trials.
MSC-based therapy for osteoarthritis — systematic review & meta-analysis
Quick answer: A 2026 systematic review pooled functional-outcome and pain data on mesenchymal stem cell therapy for osteoarthritis across multiple trials.
This review brought together mesenchymal stem cell-based approaches to osteoarthritis, pooling both functional outcome measures and pain scores to give a broader picture of reported results. See our Osteoarthritis treatment page for related protocol details.
MSC therapy for rheumatoid arthritis — systematic review & meta-analysis of clinical trials
Quick answer: A 2023 meta-analysis of clinical trials found a favourable safety profile for MSC therapy in rheumatoid arthritis, with no life-threatening events, and a trend toward clinical efficacy needing confirmation in larger trials.
Pooling 358 patients from randomized and non-randomized trials, this review found encouraging response rates (ACR20/50/70) in the MSC group versus control, while noting the evidence base is still limited in trial size. See our Rheumatoid Arthritis treatment page.
- Osteoarthritis data spans both pain scores and functional outcome measures, not pain relief alone.
- The osteoarthritis review (2026) is the most recently published study in the entire library.
- Rheumatoid arthritis evidence shows a favourable safety trend, but trial sizes remain small (358 patients pooled) — the authors call for larger RCTs before firm efficacy conclusions.
What does the research say about stem cells for diabetic foot ulcers & liver cirrhosis?
Evidence relevant to slow-healing wounds linked to diabetes and peripheral vascular disease, plus liver function outcomes in cirrhosis.
Autologous stem cells for diabetic foot ulcers — meta-analysis
Quick answer: A meta-analysis pooling multiple trials found autologous (a patient's own) stem cells associated with improved wound-healing outcomes in diabetic foot ulcers.
This meta-analysis pooled wound-healing outcomes from studies using a patient's own stem cells for diabetic foot ulcers, a complication that carries a heightened amputation risk in patients with severe peripheral vascular disease or neuropathy. See our Diabetic Foot Ulcers treatment page.
MSC therapy for liver cirrhosis — systematic review & meta-analysis
Quick answer: A 2023 meta-analysis of 11 clinical trials found MSC infusion improved liver function markers (higher albumin, lower MELD score) in cirrhosis patients, with no severe adverse effects reported.
Pooling 11 clinical trials, this review found consistent improvement in albumin levels and MELD score at multiple follow-up points, with hepatic arterial injection favouring the strongest results. See our Liver Disease treatment page.
- Autologous sourcing (the patient's own cells) is the specific approach the diabetic foot ulcer meta-analysis evaluated — not donor-derived cells.
- Diabetic foot ulcers are highlighted because of their link to amputation risk in advanced peripheral vascular disease.
- In liver cirrhosis, route of administration mattered — hepatic arterial injection showed stronger results than other delivery routes in the pooled data.
- None of the 11 liver cirrhosis trials included reported severe adverse effects.
What does the research say about exosome-based therapy?
A look at exosomes as a delivery platform across several fields of medicine, and where the science currently stands.
Exosome-based drug delivery: a next-generation platform across multiple conditions
Quick answer: A broad review describes exosomes as an emerging drug-delivery platform across cancer, infectious disease, neurological/immunological conditions, gene therapy, and regenerative medicine.
This wide-ranging review maps out where exosome-based delivery science stands today and where the field is heading. See Exosome Therapy in India for how this applies to our supportive-therapy offerings.
Exosomes and hair regeneration — systematic review across alopecia types & exosome sources
Quick answer: A 2025 systematic review of 11 clinical studies (298 patients) found MSC-derived exosomes associated with increased hair density (9.5–35 hairs/cm²) and hair thickness (up to 13.01 µm) in androgenetic alopecia, with no serious adverse events.
Pooling 11 clinical studies — including 2 RCTs — across exosomes sourced from adipose tissue, placenta, hair follicles, bone marrow, foreskin and umbilical cord, this review found consistent gains in hair density and thickness with a favourable safety profile, though evidence remains limited by small sample sizes and short follow-up. See our Hair Loss treatment page and Exosome Treatment for Hair Loss.
- Exosomes are studied as a delivery mechanism, applicable across a wider range of fields than cell therapy alone.
- For hair loss specifically, 11 clinical studies now exist — a more mature evidence base than the broad drug-delivery review alone suggests, though still limited by small sample sizes.
- Adipose- and plant-extract–derived exosome formulations produced the strongest (RCT-level) evidence for hair density and thickness gains.
- No serious adverse events were reported across any of the 11 hair-loss studies pooled.
What does the research say about stem cells for kidney & lung disease?
Emerging evidence on chronic kidney disease and chronic obstructive pulmonary disease (COPD) — including exosome-based approaches and preclinical (animal model) research that has not yet advanced to large human trials.
MSC-derived exosomes for chronic kidney disease — meta-analysis
Quick answer: A 2025 meta-analysis of 17 studies (15 preclinical, 6 clinical) found MSC-derived exosomes associated with improved kidney function markers and reduced renal fibrosis in chronic kidney disease.
Pooling both preclinical and clinical data, this review found MSC-exosome treatment linked to lower blood urea nitrogen and creatinine and higher glomerular filtration rate, with the strongest effect from bone-marrow-derived exosomes. See our Kidney Disorder treatment page.
MSC administration in COPD — preclinical systematic review & meta-analysis
Quick answer: A meta-analysis of 20 animal-model studies found MSC administration reduced lung injury and improved lung function in COPD models — this is preclinical evidence, not yet from human trials.
This review pooled 20 animal-model studies and found consistent improvement in lung tissue repair and airway inflammation markers. We include it because it is the most substantial pooled evidence available on this topic, while flagging clearly that it has not yet been confirmed in large human trials. See our Lungs Disease (COPD) treatment page.
- The kidney disease review combines both preclinical and clinical data (6 clinical studies out of 17 total) — the strongest evidence so far comes from bone-marrow-derived exosomes specifically.
- The COPD review is entirely preclinical (animal-model), included here transparently because no larger pooled human-trial evidence yet exists for this condition.
- Both reflect an earlier stage of the evidence base than the neurological and orthopaedic research above — read the "preclinical vs. clinical" distinction in our glossary before drawing conclusions.
Related evidence: see our dedicated Cardiovascular Conditions research below for heart-failure specific findings.
What does the research say about stem cell therapy for chronic heart failure?
Pooled randomized-controlled-trial evidence on mesenchymal stem cell (MSC) transplantation for chronic heart failure — covering cardiac function indices and major adverse cardiovascular events (MACE).
MSC transplantation for chronic heart failure — meta-analysis of randomized controlled trials
Quick answer: A 2024 meta-analysis of 17 RCTs (1,684 patients) found mesenchymal stem cell transplantation associated with a reduced rate of major adverse cardiovascular events and improved cardiac function indices in chronic heart failure.
Pooling 17 randomized controlled trials totalling 1,684 patients, this review assessed the effect of patient age, cause of heart failure, cell source, cell number, donor type (autologous/allogeneic), and delivery route on outcomes — finding a favourable effect on MACE alongside measurable gains in cardiac function indices. See our Cardiovascular treatment page for related protocol information.
- This is the largest single pooled patient count in the entire library — 1,684 patients across 17 RCTs.
- The review specifically modelled how donor type (autologous vs. allogeneic), cell source, and delivery route each affected outcomes, rather than treating MSC therapy as one uniform intervention.
- Findings relate to chronic heart failure specifically — not acute myocardial infarction or other cardiovascular conditions, which have a separate evidence base.
What does the research say about bone marrow transplant & stem cell–based immunotherapy?
Pooled evidence on mesenchymal stem cell (MSC) co-infusion in allogeneic bone marrow / hematopoietic stem cell transplantation, and on MSC-based immunotherapy for autoimmune and rheumatic immune diseases.
MSC co-infusion in allogeneic bone marrow / hematopoietic stem cell transplantation — systematic review & meta-analysis
Quick answer: A 2021 meta-analysis found that co-infusing mesenchymal stem cells alongside a bone marrow / hematopoietic stem cell transplant was associated with faster engraftment and a lower rate of graft-versus-host disease, without a significant change in relapse rate.
This review pooled studies comparing allogeneic bone marrow / hematopoietic stem cell transplantation with and without co-infused mesenchymal stem cells (MSCs), looking specifically at engraftment speed, acute and chronic graft-versus-host disease (GVHD), overall survival, relapse rate, and immune reconstitution. MSC co-infusion was linked to improved engraftment and reduced GVHD incidence, with no significant negative effect on relapse or survival. See our Bone Marrow Transplant treatment page for related protocol information.
MSC-based immunotherapy for autoimmune & rheumatic immune diseases — systematic review & meta-analysis of RCTs
Quick answer: A 2025 meta-analysis of 42 randomized controlled trials (2,183 participants) found mesenchymal stem cell–based immunotherapy improved outcomes in several autoimmune and rheumatic immune diseases, most consistently for spondyloarthritis, rheumatoid arthritis and primary Sjögren's syndrome.
Drawing on 42 RCTs across systemic lupus erythematosus, inflammatory bowel disease, primary Sjögren's syndrome, spondyloarthritis and other rheumatic immune conditions, this review evaluated the immunomodulatory effect of MSC transplantation, including changes in disease-activity scores and immune markers such as IgG, IgM and complement levels. Benefit was most consistent for spondyloarthritis, rheumatoid arthritis and Sjögren's syndrome, with more mixed results for other conditions. See our Immunotherapy treatment page for related protocol information.
- Co-infusing MSCs during allogeneic bone marrow / hematopoietic stem cell transplant was linked to faster engraftment and less graft-versus-host disease, without a significant change in relapse rate.
- The 2025 immunotherapy review pooled 42 RCTs and 2,183 participants across five categories of autoimmune and rheumatic immune disease — one of the largest RCT-based pools in this library.
- MSC-based immunotherapy benefit was most consistent for spondyloarthritis, rheumatoid arthritis and Sjögren's syndrome; results for other conditions were more mixed.
- Both reviews describe MSCs acting through immunomodulatory mechanisms rather than direct tissue replacement — see the "MSC" entry in our glossary.
What does the research say about stem cell therapy for vision loss?
Pooled clinical-trial evidence on stem cell therapy for degenerative, inherited and neurodegenerative eye conditions — including retinitis pigmentosa, Stargardt disease, dry age-related macular degeneration, and optic neuropathy — measured by best-corrected visual acuity (BCVA) and related outcomes.
Stem cell therapy for inherited retinal diseases — systematic review & meta-analysis
Quick answer: A 2023 meta-analysis of 21 studies found stem cell therapy improved best-corrected visual acuity at 6 months in patients with retinitis pigmentosa and Stargardt disease, with gains better sustained at 12 months for Stargardt disease.
Pooling 21 prospective studies covering 496 treated eyes, this review found meaningful short-term vision gains for both conditions, with suprachoroidal-space injection showing the strongest results for retinitis pigmentosa. Long-term improvement for retinitis pigmentosa was less consistent, underscoring the need for larger, longer-term trials. See our Retinitis Pigmentosa treatment page for related protocol information.
Stem cell transplantation for dry age-related macular degeneration — systematic review & meta-analysis
Quick answer: A 2022 meta-analysis of 10 studies (102 patients) found stem cell transplantation was associated with improved best-corrected visual acuity in patients with dry age-related macular degeneration, though the evidence base remains small.
This PROSPERO-registered review pooled 10 studies — including one randomized controlled trial — assessing visual-acuity outcomes and adverse events after stem cell transplantation for dry AMD. Intravitreal injection of bone-marrow-derived CD34+ cells was among the approaches associated with improved BCVA, while the authors caution that small sample sizes and the limited number of randomized trials mean larger, better-controlled studies are still needed. See our Macular Degeneration treatment page for related protocol information.
MSC therapy for optic neuropathy — systematic review & meta-analysis of visual acuity outcomes
Quick answer: A 2024 meta-analysis of 66 eyes across 7 studies found mesenchymal stem cell therapy improved mean visual acuity in patients with optic neuropathy, though retinal nerve fiber layer thickness did not change significantly.
This review pooled visual-acuity (LogMAR) data from 66 treated eyes across seven studies of MSC therapy for optic neuropathy, finding a statistically significant improvement in mean visual acuity after treatment. Retinal nerve fiber layer (RNFL) thickness — a structural marker of optic nerve integrity — did not change significantly, suggesting the visual gains may reflect functional rather than structural recovery. See our Optic Nerve Atrophy treatment page for related protocol information.
- Both retinitis pigmentosa and Stargardt disease showed significant BCVA improvement at 6 months post-treatment.
- Gains were better sustained at 12 months for Stargardt disease than for retinitis pigmentosa.
- Suprachoroidal-space injection showed the strongest 6-month outcomes among the administration routes studied for retinitis pigmentosa.
- In dry AMD, a smaller but PROSPERO-registered meta-analysis (10 studies, 102 patients) also found visual-acuity gains, with bone-marrow-derived CD34+ cell approaches among those showing benefit.
- In optic neuropathy, MSC therapy improved visual acuity across 66 pooled eyes, but nerve fiber layer thickness — a structural measure — did not change significantly, pointing to a functional rather than structural mechanism.
- Evidence quality across all four conditions is still limited — the authors call for larger, randomized, longer-follow-up trials.
Have questions about your condition?
Our medical team reviews every case individually. Share your reports and we'll let you know whether stem cell or exosome therapy may be appropriate for your situation — free of charge, with no obligation.
Glossary: key terms used on this page
Plain-language definitions of the recurring scientific and regulatory terms above, for readers new to the field.
- Mesenchymal Stem Cells (MSCs)
- A type of adult stem cell, commonly sourced from bone marrow, fat tissue, or umbilical cord tissue, studied for its ability to support tissue repair and modulate inflammation.
- Exosomes
- Tiny cell-secreted particles that carry proteins and genetic material between cells, studied as a delivery vehicle in regenerative medicine and drug delivery research.
- Systematic Review
- A structured, methodical survey of all available studies on a specific question, designed to minimise bias in how evidence is selected and summarised.
- Meta-Analysis
- A statistical method that combines numerical results from multiple studies into a single pooled estimate, typically used alongside a systematic review.
- Autologous
- Describes cells or tissue taken from and used on the same patient — as opposed to "allogeneic," which comes from a donor.
- ICMR
- The Indian Council of Medical Research — the body whose guidelines currently classify most stem cell applications in India as investigational rather than approved treatment.
- Investigational Therapy
- A treatment still being studied for safety and effectiveness, and not yet formally approved as a standard-of-care cure by the relevant regulatory body.
- PubMed / PubMed Central (PMC)
- Free databases run by the U.S. National Library of Medicine that index peer-reviewed biomedical research — the source for every citation on this page.
- Preclinical vs. Clinical Study
- A preclinical study is conducted in animal models or lab settings, before human testing. A clinical study or trial involves human participants. Preclinical results often do not translate directly to human outcomes — this page labels preclinical studies clearly wherever they appear.
Articles you may find interesting
Coverage on the wider regulatory and scientific conversation around stem cell therapy.
Where to find us
Stem Cell Care India
Frequently asked questions
Common questions about how this research library relates to treatment at Stem Cell Care India — written to directly answer how people naturally ask these questions in search and voice assistants.
Are the studies on this page Stem Cell Care India's own clinical data?
No. Every study listed here is an independent, peer-reviewed publication sourced from PubMed or PubMed Central. None of it represents SCCI's own clinical trial results — it's provided so you can read the wider scientific evidence behind each treatment area.
Is stem cell therapy an approved treatment in India?
Most applications remain investigational under current ICMR guidelines rather than approved cures, and are offered within regulated clinical research and patient-support settings.
What is the difference between a systematic review and a meta-analysis?
A systematic review is a structured survey of all available studies on a question. A meta-analysis goes a step further and statistically pools the numerical results from those studies into a single combined estimate. Most entries on this page are both.
How often is this research library updated?
The page is reviewed periodically by our medical team as new systematic reviews and meta-analyses become available on PubMed Central. The "last updated" date at the top reflects the most recent review.
Does reading this evidence tell me if I'm a candidate for treatment?
Not on its own. Suitability depends on your specific diagnosis, medical history and reports. Submit your case for a free review and our medical team will advise whether stem cell or exosome therapy may be appropriate for you.
Why do the summaries avoid quoting the original papers directly?
Summaries here are written in our own words to make dense scientific findings easier to read. Each entry links directly to the full, original paper on PubMed Central so you can review the exact methodology, data and conclusions yourself.
What conditions have the strongest published evidence on this page?
Cerebral palsy and Parkinson's disease have the most mature systematic-review evidence in this library. Osteoarthritis has the most recent (2026) publication. The MSC-based immunotherapy meta-analysis for autoimmune and rheumatic immune diseases has the largest pooled patient count (2,183 participants across 42 RCTs), followed by the chronic heart failure meta-analysis (1,684 patients across 17 RCTs). Exosome-based delivery is the earliest-stage, broadest-scope evidence included.
Is there published research on exosome therapy for hair loss?
Yes. A 2025 systematic review pooled 11 clinical studies (298 patients) on exosome-based therapy for androgenetic alopecia and other hair loss, finding increased hair density and thickness with a favourable safety profile — see our Exosome Therapy section above and our Hair Loss treatment page.
Can I discuss a specific study with a doctor before booking anything?
Yes. A free tele-consultation can be arranged so you can talk through the evidence and how it may or may not relate to your condition, with no obligation to proceed.
Does insurance cover treatments backed by this research?
Generally no. Because most stem cell applications remain investigational rather than approved treatments in India, insurance typically does not cover the cost. Instalment or financing plans may be available — ask our team for current options.
Where can I read the full original studies, not just the summaries?
Every "Read on PubMed Central" link on this page goes directly to the full, freely accessible paper on the U.S. National Library of Medicine's PMC database — including methodology, complete results, and author affiliations.
How do I contact Stem Cell Care India for a free case review?
Call +91 87430 24344 (international) or +91 78382 23336 (India), message on WhatsApp, or use the contact form — a specialist responds within 24–48 hours.
Is Stem Cell Care India's facility accredited?
The partner hospital is affiliated with NABH and NABL, and cell processing is carried out in ISO 9001/13485, GMP-compliant labs, with a Certificate of Analysis issued per batch.
What's the difference between stem cell therapy and exosome therapy?
Stem cell therapy transplants living cells into the body. Exosome therapy instead delivers the tiny signalling particles those cells secrete, without transplanting the cells themselves. The research base for exosomes is newer and generally earlier-stage than for stem cells — see our glossary and the exosome section above.
What's the difference between autologous and allogeneic stem cells?
Autologous means the cells come from the patient's own body; allogeneic means they come from a donor. Several studies on this page specify which approach they tested — for example, the diabetic foot ulcer meta-analysis specifically evaluated autologous cells.
How does Stem Cell Care India decide which studies to include on this page?
We prioritise systematic reviews and meta-analyses — study designs that pool and critically appraise multiple trials — over single case reports, and we link only to studies indexed on PubMed or PubMed Central so every claim is independently verifiable.
Why do some studies on this page show mixed or inconclusive results?
Medical research is presented as-is, including limitations the original authors flagged themselves — such as small sample sizes or non-standardised protocols. We do not omit caveats to make findings sound more definitive than the underlying data supports.
I'm an international patient — can I get a case review before travelling to India?
Yes. Submit your medical reports through our contact form or free expert opinion request, and our medical team reviews cases remotely before you commit to travel — see our International Patient Guide for visa, travel and stay logistics.
Are all the studies on this page based on human clinical trials?
Most are, but not all — the COPD study currently on this page is preclinical (animal-model) evidence, clearly labelled as such, because no larger pooled human-trial data is yet available for that condition. The chronic kidney disease review combines both preclinical and clinical studies. Always check each card's "Preclinical" or "Clinical" tag before drawing conclusions.
Does Stem Cell Care India offer treatment for every condition covered in this research library?
Coverage varies by condition and is assessed case by case based on current evidence and your individual medical reports. Visit the relevant condition treatment page, or contact our medical team to ask about your specific case.
Stem Cell Care India. "Research & Publications: Peer-Reviewed Stem Cell & Exosome Therapy Studies." Stem Cell Care India, last updated 24 August 2026. https://www.stemcellcareindia.com/research-publications/
